Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dabur Pharma Of India To Sell Majority Interest To Fresenius

This article was originally published in PharmAsia News

Executive Summary

India's Dabur Pharma agreed to sell a nearly three-quarters interest in the company to Fresenius Kabi of Singapore. Fresenius Kabi is a subsidiary of Fresenius SE, a global company based in Germany. Darbur's founder and director, Anand Burman, said his company agreed to sell Fesenius a 73.27 percent interest because it needed to integrate with a global company capable of expanding the firm more quickly. He noted Dabur has been getting its drugs approved around the world and it would not have made sense to attempt to market them by itself. (Click here for more

You may also be interested in...



Brakes May Be Put On Direct MNC Deals In India As Government Fears Threat To The Indian Drug Industry

MUMBAI - Acquisition of growing Indian firms by global pharmaceutical companies may get tough in the coming days as the government is brainstorming about how to clamp restrictions on buying controlling equity stakes in Indian entities through the automatic foreign direct investment route (FDI)

After Sell-Off, Dabur Pharma Promoters Aim At Value Creation Opportunities “Other than Generics”

MUMBAI - Having sold its generic oncology business to German infusion drugs and clinical nutrition company Fresenius Kabi, Dabur Pharma Founder Anand Burman is looking at a second source of value creation beyond generics

Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel